Acute renal failure after treatment with sunitinib in a patient with multiple myeloma

NDT Plus

Volumn 2, Issue 4, 2009, Pages 292-294

  Leung, Nelson ^a   Saucier, Nathan A ^a   Zeldenrust, Steven R ^a   Gunderson, Heidi D ^a   Cornell, Lynn D ^a  

^a MAYO CLINIC   (United States)

Author keywords

acute renal failure; drug toxicity; sunitinib

Indexed keywords

BORTEZOMIB; CD20 ANTIGEN; COTRIMOXAZOLE; CREATININE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN KAPPA CHAIN; IOTALAMIC ACID; LENALIDOMIDE; LEVOFLOXACIN; LISINOPRIL; NIFEDIPINE; OXYCODONE; PAMIDRONIC ACID; SUNITINIB; URIC ACID;

ABDOMINAL DISCOMFORT; ACUTE KIDNEY TUBULE NECROSIS; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD PRESSURE; BONE LESION; BONE MARROW BIOPSY; CALCIUM BLOOD LEVEL; CASE REPORT; CELL VACUOLE; COUGHING; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG WITHDRAWAL; DYSESTHESIA; ELECTRON MICROSCOPY; FEVER; HEAVY CHAIN DISEASE; HEMODIALYSIS; HUMAN; HYPEREMIA; HYPERTENSION; KIDNEY BIOPSY; KIDNEY CARCINOMA; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; KIDNEY INJURY; KIDNEY TUBULE BASEMENT MEMBRANE; LABELING INDEX; LEUKOCYTE COUNT; MALAISE; MALE; MULTIPLE MYELOMA; NEPHROTOXICITY; PLASMA CELL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; PROTEIN URINE LEVEL; RIB FRACTURE; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL;

EID: 77955973922     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfp037     Document Type: Article

References (10)

1. Izzedine H, Buhaescu I, Rixe O et al. Sunitinib malate. Cancer Chemother Pharmacol 2007; 60: 357-364
2. Ikezoe T, Nishioka C, Tasaka T et al. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther 2006; 5: 2522-2530
3. Patel TV, Morgan JA, Demetri GD et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008; 100: 282-284
4. Saltz LB, Rosen LS, Marshall JL et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007; 25: 4793-4799
5. Socinski MA, Novello S, Brahmer JR et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26: 650-656
6. Khurana A. Allergic interstitial nephritis possibly related to sunitinib use. Am J Geriatr Pharmacother 2007; 5: 341-344
7. Kapiteijn E, Brand A, Kroep J et al. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 2007; 18: 1745-1747
8. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136
9. Nakamura M,Yamabe H, OsawaHet al.Hypoxic conditions stimulate the production of angiogenin and vascular endothelial growth factor by human renal proximal tubular epithelial cells in culture. Nephrol Dial Transplant 2006; 21: 1489-1495
10. Wang PX, Sanders PW. Immunoglobulin light chains generate hydrogen peroxide. J Am Soc Nephrol 2007; 18: 1239-1245